A phase I and pharmacokinetic study of intravenous vinzolidine

Charles W. Taylor, Sydney E. Salmon, Winston G. Satterlee, Aurelia B. Robertone, Thomas M. McCloskey, Mark T. Holdsworth, Patricia M. Plezia, David S. Alberts

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The semi-synthetic vinca alkaloid vinzolidine was administered to advanced cancer patients as an intravenous bolus on a three day schedule every 21 days. Forty-two patients were treated in this phase I trial. Five partial remissions (breast-1, melanoma-2, renal cancer-2) were seen in 30 evaluable patients. The dose limiting toxicities were myelosuppression and neuropathy. Erratic myelosuppression from course to course within the same patient as seen in previous trials with oral vinzolidine, was not observed with the intravenous formulation. The measured pharmacokinetic parameters conformed best to a 2-compartment model with a mean terminal half-life of 23 hours. The anti-tumor activity observed during this phase I trial and acceptable toxicity provide the basis for initiating phase II studies in selected forms of cancer.

Original languageEnglish (US)
Pages (from-to)S51-S57
JournalInvestigational New Drugs
Issue number1 Supplement
StatePublished - Mar 1990


  • melanoma
  • pharmacokinetics
  • phase I
  • renal cancer
  • vinzolidine

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'A phase I and pharmacokinetic study of intravenous vinzolidine'. Together they form a unique fingerprint.

Cite this